Pharmacokinetics of intravenous and intraperitoneal cefotaxime in chronic ambulatory peritoneal dialysis
- PMID: 4028623
- DOI: 10.1038/clpt.1985.172
Pharmacokinetics of intravenous and intraperitoneal cefotaxime in chronic ambulatory peritoneal dialysis
Abstract
We investigated the kinetics of cefotaxime in eight subjects undergoing continuous ambulatory peritoneal dialysis (CAPD). A single 1 gm iv dose was injected and a 1 gm dose was given intraperitoneally in the CAPD fluid during a 4-hour dwell time. Cefotaxime and desacetylcefotaxime were assayed by HPLC. After intravenous injection the cefotaxime serum kinetic parameters were as follows: plasma t 1/2, 2.31 +/- 0.20 hours; volume of distribution, 0.35 +/- 0.04 L/kg; total plasma clearance, 118.7 +/- 12.3 ml/min; and peritoneal clearance, 6.7 +/- 1.3 ml/min. Dialysate cefotaxime concentrations rose rapidly, but only 5% of the dose was eliminated by the peritoneal route. After intraperitoneal instillation, cefotaxime appeared in the serum rapidly and the peak serum concentrations ranged from 9 to 20 micrograms/ml between 1 and 3 hours. The absorption of cefotaxime from peritoneal space was 58.7% +/- 5.4%. Data suggest that cefotaxime has bidirectional exchange characteristics through the peritoneal membrane. Instillation of cefotaxime in CAPD fluid may permit rapid absorption to achieve therapeutic serum concentrations.
Similar articles
-
Ceftizoxime elimination kinetics in continuous ambulatory peritoneal dialysis.Clin Pharmacol Ther. 1983 Nov;34(5):673-80. doi: 10.1038/clpt.1983.231. Clin Pharmacol Ther. 1983. PMID: 6313276
-
Pharmacokinetics of intravenous and intraperitoneal moxalactam in chronic ambulatory peritoneal dialysis.Eur J Clin Pharmacol. 1986;30(3):299-302. doi: 10.1007/BF00541532. Eur J Clin Pharmacol. 1986. PMID: 3732364
-
Pharmacokinetics of intravenous and intraperitoneal ceftriaxone in chronic ambulatory peritoneal dialysis.Eur J Clin Pharmacol. 1986;31(4):479-83. doi: 10.1007/BF00613528. Eur J Clin Pharmacol. 1986. PMID: 3816928 Clinical Trial.
-
Drug therapy in patients undergoing continuous ambulatory peritoneal dialysis. Clinical pharmacokinetic considerations.Clin Pharmacokinet. 1990 Feb;18(2):104-17. doi: 10.2165/00003088-199018020-00002. Clin Pharmacokinet. 1990. PMID: 2180611 Review.
-
Pharmacokinetics of cefotaxime in dialysis patients.Diagn Microbiol Infect Dis. 1995 May-Jun;22(1-2):85-7. doi: 10.1016/0732-8893(95)00086-p. Diagn Microbiol Infect Dis. 1995. PMID: 7587055 Review.
Cited by
-
Pharmacokinetics of cefotaxime and its desacetyl metabolite in plasma and in cerebrospinal fluid.Eur J Drug Metab Pharmacokinet. 1987 Apr-Jun;12(2):91-102. doi: 10.1007/BF03189882. Eur J Drug Metab Pharmacokinet. 1987. PMID: 3691581
-
Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.Drugs. 1997 Mar;53(3):483-510. doi: 10.2165/00003495-199753030-00009. Drugs. 1997. PMID: 9074846 Review.
-
Teicoplanin pharmacokinetics in patients with chronic renal failure.Clin Pharmacokinet. 1987 Apr;12(4):292-301. doi: 10.2165/00003088-198712040-00003. Clin Pharmacokinet. 1987. PMID: 2954735
-
Cefotaxime. An update of its pharmacology and therapeutic use.Drugs. 1990 Oct;40(4):608-51. doi: 10.2165/00003495-199040040-00008. Drugs. 1990. PMID: 2083516 Review.
-
Pharmacokinetics of intraperitoneal teicoplanin in patients with chronic renal failure on continuous ambulatory peritoneal dialysis.Br J Clin Pharmacol. 1988 Jun;25(6):761-5. doi: 10.1111/j.1365-2125.1988.tb05265.x. Br J Clin Pharmacol. 1988. PMID: 2974299 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources